Verification evidence is still being completed.
PDF / print export
intoDNA S.A.
Krakow, Poland
- Verified lead
- Magda Kordon
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer and Co-Founder
- 2026 technical specialization
- DNA-Break Biomarker Detection, PARP and DDR Biomarker Services, and Companion Diagnostics
- Review cycle
- 24 April 2026
- Full address
- ul. Profesora Michala Bobrzynskiego 14, 30-348 Krakow, Poland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- intoDNA About Us page naming Magda Kordon as CEO and Co-founder.
- Editorial note
- Krakow precision-oncology biomarker biotech with named co-founder CEO, the STRIDE DNA-break platform, and a clear DDR and PARP biomarker services focus.
DNA-Break Biomarker Detection, PARP and DDR Biomarker Services, and Companion Diagnostics
Public co-founder CEO disclosure, Kafkadesk founder profile, STRIDE biomarker platform documentation
Krakow precision-oncology biomarker biotech with named co-founder CEO, the STRIDE DNA-break platform, and a clear DDR and PARP biomarker services focus.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Krakow, Poland
intoDNA S.A.
DNA-Break Biomarker Detection, PARP and DDR Biomarker Services, and Companion Diagnostics · Biomarker services operation
Krakow precision-oncology biomarker biotech with named co-founder CEO, the STRIDE DNA-break platform, and a clear DDR and PARP biomarker services focus.
- Lead
- Magda Kordon (verified ↗)
- Address
- ul. Profesora Michala Bobrzynskiego 14, 30-348 Krakow, Poland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Biomarker services operation
- Capabilities
- STRIDE DNA-Break Biomarker Platform · DDR and PARP Inhibitor Biomarker Services · Companion Diagnostic Development
- Founded
- 2016
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Magda Kordon
Chief Executive Officer and Co-Founder
Full addressul. Profesora Michala Bobrzynskiego 14, 30-348 Krakow, Poland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Franowo Centrum directory listing intoDNA at Bobrzynskiego 14 in Krakow.
Open sourceBiomarker services operation
Krakow, Poland. DNA-Break Biomarker Detection, PARP and DDR Biomarker Services, and Companion Diagnostics. Review completed on 24 Apr 2026.
Polish Office for Registration of Medicinal Products and EU IVDR for future launches
Public co-founder CEO disclosure, Kafkadesk founder profile, STRIDE biomarker platform documentation
DNA-Break Biomarker Detection, PARP and DDR Biomarker Services, and Companion Diagnostics
Krakow precision-oncology biomarker biotech with named co-founder CEO, the STRIDE DNA-break platform, and a clear DDR and PARP biomarker services focus.
Editorial note
intoDNA anchors Polish precision-oncology biomarker services with a named co-founder CEO, a proprietary STRIDE DNA-break assay, and a Krakow technology-park base.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
STRIDE DNA-Break Biomarker Platform
DDR and PARP Inhibitor Biomarker Services
Companion Diagnostic Development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
STRIDE DNA-break assay
Preclinical oncology biomarker workflow
Companion-diagnostic development
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is intoDNA S.A. located?
- intoDNA S.A. operates from ul. Profesora Michala Bobrzynskiego 14, 30-348 Krakow, Poland, Krakow, Poland.
- Who runs intoDNA S.A.?
- intoDNA S.A. is led by Magda Kordon, Chief Executive Officer and Co-Founder. Verified 24 Apr 2026.
- What does intoDNA S.A. do?
- Krakow precision-oncology biomarker biotech with named co-founder CEO, the STRIDE DNA-break platform, and a clear DDR and PARP biomarker services focus. Core capabilities: STRIDE DNA-Break Biomarker Platform, DDR and PARP Inhibitor Biomarker Services, Companion Diagnostic Development.
Editorial context
Related technical briefs
Briefs that name Krakow as a covered market or city.